HIV/AIDS prophylaxis in British Columbia

Last updated

In January 2018, the provincial government of British Columbia (BC) began providing individuals at high risk of HIV infection with pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) at no cost. [1] High risk individuals include men and trans women who have sex with men, people who inject drugs, and people who have sex with people living with HIV. [1] One year following this policy change, which is delivered as part of the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE)'s Drug Treatment Program, almost 3,300 people have been prescribed with PrEP or PEP. [2]

Contents

The steps for obtaining PrEP in BC are as follows: speaking to a physician, getting some medical tests, enrolling and being given a prescription, and refilling the prescription. [3] The effort was undertaken to better support the UNAIDS "90-90-90: treatment for all" targets. [4]

HIV/AIDS in British Columbia

As part of the global HIV/AIDS epidemic, [5] BC experienced two distinct periods of rapid incidence growth rate. The first was in the 1980s among men who have sex with men, and the second was in the 1990s among injection drug users. [6] At its peak in 1987, the rate of new HIV diagnoses in BC was roughly 31 cases per 100,000 population. [7] The BC HIV incidence rate decreased thereafter and it was not until 2010 that the BC HIV incidence rate was less than the Canadian HIV incidence rate (7 per 100,000 population). [7] As of 2017, the rate of new HIV cases reported in BC was 3.8 per 100,000 population. [8]

Current state

As summarized in the BC Centre for Disease Control's Annual Surveillance Report, rates of new HIV cases differ based on location, gender, ethnicity, sexual orientation, and intravenous drug use. In addition to new HIV cases being highest in the Vancouver Coastal and Island Health Authorities, they were also highest among males, Caucasians (43% of new cases), gay, bisexual and other men who have sex with men (gbMSM), [9] and among people who inject drugs. [8] The dramatic decrease in new HIV cases among people who inject drugs is the main reason why the overall rate of new HIV cases has decreased. [8] With an incidence rate of 182 cases, [8] there are approximately 7,200 people living with HIV in BC. [10]

Policy effects

This policy has expanded access to preventative HIV medication in British Columbia. Individuals at high risk of contracting HIV can apply to receive PrEP no cost. The out-of-pocket cost of emtricitabine/tenofovir, a medication used to prevent HIV, was previously between $250 and $1,000 per month. [11] Because the BC-CfE was able to negotiate a lower price with manufacturers of generic versions of Truvada, [12] the program is able to offer the drug at no cost for high risk individuals. In its first six months, the program cost the BC government around $300,000. [13] Of the nearly 3,300 people being prescribed PrEP through this new policy, 98.4% are male, 0.5% are female, and 1.1% identify as transgender, unspecified, or another form of gender identity. [10] Provincial health authorities estimate that once the program has 5,000 participants, the rate of new HIV cases in BC will fall by 83% by 2026. [13]

Another positive consequence is an uptake in the number of PEP kits being used. Between 2017 and 2018 there was a 23% increase in the number of PEP kit initiations, bringing the number of kit initiations up to 400. [14]

There are also potential long-term savings to government through reduced healthcare costs. By preventing HIV infections, the BC government will save on the lifetime cost of antiretroviral therapy drugs and hospital costs for HIV/AIDS-related treatment. [15] In the German setting, investing in PrEP coverage has a projected savings of €5.1 billion Euros over a 40-year period. [16] In the United States, the medical cost savings for each case of HIV prevented is roughly US$229,800. [17]

Coverage in other areas of Canada

Other considerations

Safe sex

Since PrEP only protects against HIV and does not protect against blood-borne infections (e.g., hepatitis C) or other STIs (e.g., herpes, syphilis, chlamydia, gonorrhoea), [32] there is concern that increasing access to PrEP may increase rates of sexually transmitted infections by encouraging fewer safe sex practices like condom use. [33] [34] Others find evidence that suggests access to PrEP actually decreases the number of sexual partners and the number of men reporting unprotected anal sex. [35]

Barriers to access

Another policy consideration is potential barriers to access. Of current prescribers, 88% pick their medication up directly from St. Paul's hospital while 12% have the medication shipped to their physician's office outside of Vancouver. [36] While the bulk of the program participants live in Metro Vancouver, [2] there is ongoing concern that physician knowledge and access to primary care physicians in areas outside of Metro Vancouver are preventing access. To sign up for the program, a potential participant needs to have a physician submit a form on their behalf to the BC-CfE. Not everyone at risk of contracting HIV has a primary care physician or a physician they feel comfortable enough talking with about their sexual activity and previous drug use. [36] Also, some physicians refuse to fill out the prescription, citing process complexity or instead suggesting the person engage in fewer risky behaviours. [36]

References

  1. 1 2 Ministry of Health (December 28, 2017). "Preventative medication will protect people at risk of HIV". BC Gov News. Retrieved October 27, 2019.
  2. 1 2 Ministry of Health (March 7, 2019). "One year of preventing new HIV infections throughout BC". BC Gov News. Retrieved October 29, 2019.
  3. "How do I get PrEP?". Health Initiative For Men - HIM. 14 December 2017. Retrieved 2019-10-29.
  4. "90-90-90: treatment for all". www.unaids.org. Retrieved 2019-10-29.
  5. "Why the HIV epidemic is not over". World Health Organization
  6. McInnes, Colin W; Druyts, Eric; Harvard, Stephanie S; Gilbert, Mark; Tyndall, Mark W; Lima, Viviane D; Wood, Evan; Montaner, Julio SG; Hogg, Robert S (2009). "HIV/AIDS in Vancouver, British Columbia: a growing epidemic". Harm Reduction Journal. 6 (1): 5. doi: 10.1186/1477-7517-6-5 . ISSN   1477-7517. PMC   2662822 . PMID   19265531.
  7. 1 2 BC Centre for Disease Control (2018). "HIV in British Columbia: Annual Surveillance Report 2016" (PDF). Retrieved November 4, 2019.
  8. 1 2 3 4 BC Centre for Disease Control (2017). "HIV: Annual report" (PDF). BC Centre for Disease Control. Retrieved October 29, 2019.
  9. Hull, Mark; Edward, Joshua; Leah, Kelly (March 27, 2017). "PEP/PrEP Update - A BC Case Study" (PDF). CATIE: Canada's Source for HIV and Hepatitis C Information. Retrieved November 4, 2019.
  10. 1 2 Health (2019-03-07). "One year of preventing new HIV infections throughout B.C." news.gov.bc.ca. Retrieved 2019-11-05.
  11. Smith, Alex. "How to access PrEP without insurance in Canada (for $45 CAD per month)". Davie Buyers Club. Retrieved October 29, 2019.
  12. Penner, Derrick (2017-12-29). "B.C. to offer free HIV prevention treatment to high-risk individualspublisher=Vancouver Sun" . Retrieved 2019-11-05.
  13. 1 2 "Over 2,000 people in BC are now prescribed on new life-saving HIV prevention drug | News". dailyhive.com. Retrieved 2019-11-05.
  14. Health (2018-06-26). "Celebrating six months of success preventing new HIV infections throughout B.C." news.gov.bc.ca. Retrieved 2019-11-06.
  15. Adshade, Marina; Bell, Niko (January 7, 2018). "Governments should fund birth control, as they do HIV prevention". The Globe and Mail. Retrieved November 5, 2019.
  16. van de Vijver, David A M C; Richter, Ann-Kathrin; Boucher, Charles A B; Gunsenheimer-Bartmeyer, Barbara; Kollan, Christian; Nichols, Brooke E; Spinner, Christoph D; Wasem, Jürgen; Schewe, Knud; Neumann, Anja (2019-02-14). "Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058". Eurosurveillance. 24 (7). doi:10.2807/1560-7917.ES.2019.24.7.1800398. ISSN   1560-7917. PMC   6381659 . PMID   30782266.
  17. Schackman, Bruce R.; Fleishman, John A.; Su, Amanda E.; Berkowitz, Bethany K.; Moore, Richard D.; Walensky, Rochelle P.; Becker, Jessica E.; Voss, Cindy; Paltiel, A. David; Weinstein, Milton C.; Freedberg, Kenneth A. (2015). "The Lifetime Medical Cost Savings From Preventing HIV in the United States". Medical Care. 53 (4): 293–301. doi:10.1097/MLR.0000000000000308. ISSN   0025-7079. PMC   4359630 . PMID   25710311.
  18. "PrEP Alberta | Finding Insurance Coverage". prepalberta. Archived from the original on 2019-10-30. Retrieved 2019-11-06.
  19. "HIV PrEP". www.rqhealth.ca. Retrieved 2019-11-06.
  20. "Pre-Exposure Prophylaxis (PrEP)". Manitoba HIV Program. 21 August 2025. Retrieved 21 August 2025.{{cite web}}: CS1 maint: url-status (link)
  21. AIDS Committee of Toronto. "PrEP in Ontario – Update for Community" (PDF). Retrieved November 5, 2019.
  22. Paré, Étienne. "Québec refuse de rendre gratuit un médicament essentiel à la prévention du sida". Le Journal de Montréal. Retrieved 2019-11-06.
  23. "La PrEP". www.rezosante.org (in French). Retrieved 2019-11-06.
  24. Ministry of Health and Wellness (July 20, 2018). "Government Adds HIV Prevention Drug to Public Health Plan". Government of Nova Scotia. Retrieved November 5, 2019.
  25. "Nova Scotia adds an HIV prevention drug to the pharmacare program after an increase of new infections | The Star". The Toronto Star. 20 July 2018. Retrieved 2019-11-06.
  26. "PrEP – AIDS New Brunswick | SIDA Nouveau-Brunswick" . Retrieved 2019-11-06.
  27. "Approval of the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the transmission of HIV". AIDS Committee of Newfoundland and Labrador. 2018-11-26. Archived from the original on 2019-11-06. Retrieved 2019-11-06.
  28. "HIV Drug Program". Prince Edward Island. February 13, 2025. Retrieved 21 August 2025.{{cite web}}: CS1 maint: url-status (link)
  29. "Preventative human immunodeficiency virus (HIV) prescription coverage coming to Yukon". Yukon.ca. 2020-12-04. Retrieved 2025-08-21.{{cite web}}: CS1 maint: url-status (link)
  30. "HIV PrEP for Yukoners Brochure" (PDF). Yukon.ca. 2025-08-21. Retrieved 2025-08-21.{{cite web}}: CS1 maint: url-status (link)
  31. 1 2 Toronto General Hospital, Immunodeficiency Clinic (2018). "Provincial/Territorial Coverage of ARV drugs for HIV prevention across Canada" (PDF). CATIE: Canada's source for HIV and hepatitis C information. Retrieved November 5, 2019.
  32. "Oral pre-exposure prophylaxis (PrEP)". www.catie.ca. Archived from the original on 2019-10-31. Retrieved 2019-11-06.
  33. Bond, Keosha T.; Gunn, Alana J. (2016). "Perceived Advantages and Disadvantages of Using Pre-Exposure Prophylaxis (PrEP) among Sexually Active Black Women: An Exploratory Study". Journal of Black Sexuality and Relationships. 3 (1): 1–24. doi:10.1353/bsr.2016.0019. ISSN   2376-7510. PMC   5512598 . PMID   28725660.
  34. Wise, Jacqui (2018-06-06). "Pre-exposure prophylaxis may increase risky behaviour when introduced, study finds". BMJ: k2514. doi:10.1136/bmj.k2514. ISSN   0959-8138. S2CID   46965502.
  35. Liu, Albert Y.; Vittinghoff, Eric; Chillag, Kata; Mayer, Kenneth; Thompson, Melanie; Grohskopf, Lisa; Colfax, Grant; Pathak, Sonal; Gvetadze, Roman; OʼHara, Brandon; Collins, Brandi (2013). "Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States". Journal of Acquired Immune Deficiency Syndromes. 64 (1): 87–94. doi:10.1097/QAI.0b013e31828f097a. ISSN   1525-4135. PMC   3904758 . PMID   23481668.
  36. 1 2 3 "HIV pre-exposure drug approved for funding in B.C., but barriers remain". The Globe and Mail. Retrieved 2019-11-06.